Skip to main content
. 2019 Aug 29;10(4-6):161–167. doi: 10.1007/s12672-019-00367-0

Fig. 2.

Fig. 2

Overall survival patients with liver metastases treated with regional therapy (N = 23). Median OS from time of treatment initiation for metastatic disease was longer for patients treated with TACE or SIRT (N = 6) compared to those who were not (N = 17) (32.4 months (95% CI 17.1–70.2) vs 9.9 months (95% CI 3.3–18.8); (p = 0.011))